# OnCo record paper-abida-msi-prostate-checkpoint-blockade-jama-oncol-2019 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-abida-msi-prostate-checkpoint-blockade-jama-oncol-2019/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-abida-msi-prostate-checkpoint-blockade-jama-oncol-2019" ;
  schema:name "Prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade"@en ;
  schema:description "Three in a hundred prostate cancers have a broken proofreading system, and in the men who did, immunotherapy worked and kept working."@en ;
  schema:url <https://onco.cc/key-papers/paper-abida-msi-prostate-checkpoint-blockade-jama-oncol-2019/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jamaoncol.2018.5801>, <https://pubmed.ncbi.nlm.nih.gov/30589920/> ;
  schema:sameAs <https://doi.org/10.1001/jamaoncol.2018.5801> ;
  schema:datePublished "2019"^^xsd:gYear ;
  schema:author "Abida W, Cheng ML, Armenia J, et al." ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:technologies <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/msh2/>, <https://onco.cc/targets/msh6/>, <https://onco.cc/targets/mlh1/>, <https://onco.cc/targets/pms2/>, <https://onco.cc/targets/mmr/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:pathways <https://onco.cc/pathways/mismatch-repair-msi/>, <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/cancer-immunity-cycle/> ;
  onco:terms <https://onco.cc/terms/msi/>, <https://onco.cc/terms/lynch-syndrome/>, <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/terms/germline-vs-somatic/>, <https://onco.cc/terms/psa50/> ;
  onco:journals <https://onco.cc/journals/jama-oncology/> .